Credit Suisse Group AG reaffirmed their neutral rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Monday morning. The brokerage currently has a $123.00 target price on the stock.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Co. reiterated a buy rating on shares of Johnson & Johnson in a report on Monday, July 11th. Leerink Swann reiterated a buy rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Zacks Investment Research upgraded Johnson & Johnson from a hold rating to a buy rating and set a $139.00 price objective on the stock in a report on Friday, August 5th. Deutsche Bank AG reiterated a buy rating and set a $142.00 price objective on shares of Johnson & Johnson in a report on Friday, August 19th. Finally, Vetr upgraded Johnson & Johnson from a hold rating to a buy rating and set a $124.21 price objective on the stock in a report on Monday, August 22nd. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of Hold and an average target price of $119.53.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.91 on Monday. The company has a market cap of $325.32 billion, a PE ratio of 22.16 and a beta of 0.61. Johnson & Johnson has a 12 month low of $89.90 and a 12 month high of $126.07. The firm’s 50-day moving average price is $120.26 and its 200-day moving average price is $116.14.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. Equities analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a $0.80 dividend. The ex-dividend date was Friday, August 19th. This represents a $3.20 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 60.15%.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the company. Trust Co. of Virginia VA boosted its stake in Johnson & Johnson by 8.3% in the first quarter. Trust Co. of Virginia VA now owns 93,345 shares of the company’s stock valued at $10,100,000 after buying an additional 7,161 shares in the last quarter. New England Research & Management Inc. boosted its stake in Johnson & Johnson by 3.6% in the first quarter. New England Research & Management Inc. now owns 26,130 shares of the company’s stock valued at $2,827,000 after buying an additional 900 shares in the last quarter. Indiana Trust & Investment Management CO boosted its stake in Johnson & Johnson by 3.1% in the first quarter. Indiana Trust & Investment Management CO now owns 13,259 shares of the company’s stock valued at $1,435,000 after buying an additional 395 shares in the last quarter. Stock Yards Bank & Trust Co. boosted its stake in Johnson & Johnson by 3.3% in the first quarter. Stock Yards Bank & Trust Co. now owns 81,147 shares of the company’s stock valued at $8,780,000 after buying an additional 2,555 shares in the last quarter. Finally, First American Trust FSB boosted its stake in Johnson & Johnson by 1,942.4% in the first quarter. First American Trust FSB now owns 50,427 shares of the company’s stock valued at $5,456,000 after buying an additional 47,958 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.